Mesoblast (ASX:MSB) expanded its coverage for Ryoncil to 104 million US government- and private-insured lives, according to a Thursday filing with the Australian bourse.
Ryoncil is approved by the US Food and Drug Administration for mesenchymal stromal cell therapy.
It is the only approved therapy for steroid-refractory acute graft versus host disease (SR-aGvHD) in children aged two months and older, a separate filing showed.
Mesoblast's shares were up nearly 2% in recent trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。